The DNAL1 Knockout SK-HEP-1 Polyclonal Cells represent a polyclonal cell population derived from the SK-HEP-1 human liver sinusoidal endothelial-like cell line, in which the DNAL1 gene has been disrupted using CRISPR/Cas9-mediated genome editing. This knockout product offers a loss-of-function model to study DNAL1-dependent processes without clonal selection, providing a heterogeneous population that reflects the complexity of gene disruption across a pool of cells. The polyclonal format is advantageous for capturing a range of knockout efficiencies and functional outcomes, enabling robust assessment of DNAL1??s role in cellular processes. Researchers can utilize these cells to investigate ciliary biology and associated signaling pathways in a liver endothelial context, supporting studies from basic mechanism to therapeutic screening.
SK-HEP-1 cells were originally isolated from the ascites of a patient with liver adenocarcinoma and exhibit a unique combination of endothelial and epithelial characteristics. These cells are widely used as a model system for hepatic endothelium, providing a platform to examine endothelial barrier function, tumor cell adhesion, transendothelial migration, and drug metabolism. Their hybrid phenotype allows the study of endothelial?Cmesenchymal transition and the interplay between epithelial and endothelial signaling programs. In the context of DNAL1 knockout, SK-HEP-1 cells serve as a relevant host to explore ciliary function and signaling in liver sinusoidal endothelial-like cells, which are critical for liver physiology and pathology.
DNAL1 encodes a light chain component of the outer dynein arm of ciliary axonemes and is essential for ciliary motility and mucociliary clearance. The gene is transcriptionally regulated by FOXJ1, RFX2, and RFX3, and its expression is modulated by NOTCH signaling. The DNAL1 protein interacts with several dynein chains including DNAI1, DNAH5, DNAI2, and DNALI1, and requires assembly factors such as DNAAF1, DNAAF2, and DNAAF3 for proper incorporation into the outer dynein arm complex. Disruption of DNAL1 abolishes outer dynein arm assembly, leading to loss of ciliary beat frequency and impaired cilia-dependent signaling. In particular, primary cilia-mediated Hedgehog and Wnt pathways are compromised, as evidenced by altered downstream targets including IFT88, SMO, and GLI1. Thus, DNAL1 knockout cells are a valuable tool for dissecting the intersection of ciliary structure and signal transduction.
In the SK-HEP-1 host cell line, the loss of DNAL1 function is expected to disrupt ciliogenesis and cilia-dependent signaling, which may have significant consequences for cell behavior. Liver endothelial cells are known to possess primary cilia that sense flow and regulate signaling pathways like Hedgehog and Wnt, influencing cell proliferation, migration, and barrier integrity. Consequently, DNAL1 knockout in these cells can be used to model the impact of ciliary dysfunction on endothelial biology, including alterations in cell migration and metastatic potential. This model therefore bridges the fields of ciliopathy research and hepatology, offering insights into how motile cilia protein defects affect non-motile signaling in a liver-relevant cellular environment.
These DNAL1 knockout polyclonal cells are suitable for a wide range of research applications, including modeling primary ciliary dyskinesia at a molecular level, investigating ciliary signaling in liver endothelial biology, studying ciliopathy mechanisms in cancer, and screening potential therapeutic agents that target ciliary assembly or signaling. Representative assays include western blotting and RT-qPCR to assess expression of DNAL1 and ciliary markers, immunofluorescence for acetylated ??-tubulin and ??-tubulin to visualize cilia, Sanger sequencing to confirm CRISPR target site disruption, cilia formation assays, wound-healing migration assays, Hedgehog transcriptional reporter assays, and co-immunoprecipitation of outer dynein arm components. For further information or to discuss specific experimental needs, please contact Ascent Research.
